MDPI and ACS Style
Xavier, A.E.T.; Veronez, L.C.; Nagano, L.F.P.; Correa, C.A.P.; Baroni, M.; Ramos, M.S.; Queiroz, R.d.G.d.P.; Fernandes Molina, C.A.; Yunes, J.A.; Brandalise, S.R.;
et al. Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line. Cancers 2024, 16, 1094.
https://doi.org/10.3390/cancers16061094
AMA Style
Xavier AET, Veronez LC, Nagano LFP, Correa CAP, Baroni M, Ramos MS, Queiroz RdGdP, Fernandes Molina CA, Yunes JA, Brandalise SR,
et al. Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line. Cancers. 2024; 16(6):1094.
https://doi.org/10.3390/cancers16061094
Chicago/Turabian Style
Xavier, Alcides Euzebio Tavares, Luciana Chain Veronez, Luís Fernando Peinado Nagano, Carolina Alves Pereira Correa, Mirela Baroni, Milena Silva Ramos, Rosane de Gomes de Paula Queiroz, Carlos Augusto Fernandes Molina, José Andres Yunes, Silvia Regina Brandalise,
and et al. 2024. "Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line" Cancers 16, no. 6: 1094.
https://doi.org/10.3390/cancers16061094
